Posted by Michael Wonder on 04 Dec 2024
Anavex Life Sciences announces submission of blarcamesine MAA for treatment of Alzheimer’s disease to EMA
26 November 2024 - First marketing authorisation submission for blarcamesine.
Anavex Life Sciences today announced the submission of the blarcamesine (ANAVEX 2-73) marketing authorisation application to the EMA.
